Jazz director sells 1,157 shares in plan trade
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc director Mark Douglas Smith reported an open-market sale of 1,157 ordinary shares at $230.55 per share. After this transaction, he directly holds 9,680 ordinary shares. According to a disclosed Rule 10b5-1 trading plan adopted on March 9, 2026, the sale occurred automatically and was not a discretionary trade.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 1,157 | $230.55 | $267K |
Footnotes (1)
- F1. This transaction was made pursuant to a plan adopted by the reporting person on March 9, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
Key Figures
Key Terms
Rule 10b5-1 regulatory
open-market sale financial
Securities Exchange Act of 1934 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Mark Douglas Smith?
Was the Jazz Pharmaceuticals (JAZZ) insider sale by Mark Douglas Smith discretionary?
What does the Rule 10b5-1 plan disclosure mean for this Jazz Pharmaceuticals (JAZZ) trade?
AI-generated analysis. How Rhea-AI works. Not financial advice.